JP6862348B2 - アルブミン融合タンパク質を精製する方法 - Google Patents

アルブミン融合タンパク質を精製する方法 Download PDF

Info

Publication number
JP6862348B2
JP6862348B2 JP2017548053A JP2017548053A JP6862348B2 JP 6862348 B2 JP6862348 B2 JP 6862348B2 JP 2017548053 A JP2017548053 A JP 2017548053A JP 2017548053 A JP2017548053 A JP 2017548053A JP 6862348 B2 JP6862348 B2 JP 6862348B2
Authority
JP
Japan
Prior art keywords
sequence
seq
loop
comprises seq
loop comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017548053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513124A (ja
JP2018513124A5 (enExample
Inventor
パブスト，ティモシー
フォンセカ，マリコ
トンプソン，クリストファー
ハンター，アラン
ワン，シアンヤン
ティエ，リウ
リー，イミン
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2018513124A publication Critical patent/JP2018513124A/ja
Publication of JP2018513124A5 publication Critical patent/JP2018513124A5/ja
Priority to JP2021061713A priority Critical patent/JP7320550B2/ja
Application granted granted Critical
Publication of JP6862348B2 publication Critical patent/JP6862348B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017548053A 2015-03-12 2016-03-11 アルブミン融合タンパク質を精製する方法 Active JP6862348B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021061713A JP7320550B2 (ja) 2015-03-12 2021-03-31 アルブミン融合タンパク質を精製する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562132198P 2015-03-12 2015-03-12
US62/132,198 2015-03-12
PCT/US2016/022003 WO2016145307A1 (en) 2015-03-12 2016-03-11 Method of purifying albumin-fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021061713A Division JP7320550B2 (ja) 2015-03-12 2021-03-31 アルブミン融合タンパク質を精製する方法

Publications (3)

Publication Number Publication Date
JP2018513124A JP2018513124A (ja) 2018-05-24
JP2018513124A5 JP2018513124A5 (enExample) 2019-04-18
JP6862348B2 true JP6862348B2 (ja) 2021-04-21

Family

ID=56878920

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017548053A Active JP6862348B2 (ja) 2015-03-12 2016-03-11 アルブミン融合タンパク質を精製する方法
JP2021061713A Active JP7320550B2 (ja) 2015-03-12 2021-03-31 アルブミン融合タンパク質を精製する方法
JP2023080507A Pending JP2023103368A (ja) 2015-03-12 2023-05-16 アルブミン融合タンパク質を精製する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021061713A Active JP7320550B2 (ja) 2015-03-12 2021-03-31 アルブミン融合タンパク質を精製する方法
JP2023080507A Pending JP2023103368A (ja) 2015-03-12 2023-05-16 アルブミン融合タンパク質を精製する方法

Country Status (10)

Country Link
US (3) US10683340B2 (enExample)
EP (2) EP3268389B1 (enExample)
JP (3) JP6862348B2 (enExample)
KR (2) KR20240093725A (enExample)
CN (1) CN107428817B (enExample)
AU (3) AU2016228806B2 (enExample)
CA (1) CA2977675A1 (enExample)
ES (1) ES2839211T3 (enExample)
IL (1) IL253971B (enExample)
WO (1) WO2016145307A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2771022T3 (da) 2011-10-11 2020-09-28 Viela Bio Inc Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN112423790B (zh) 2018-05-16 2025-05-16 Lib疗法股份有限公司 包含结合pcsk9的分子的组合物和使用方法
BR112021008797A2 (pt) * 2018-11-09 2021-08-31 Neopep Pharma Gmbh & Co. Kg Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
EP3711772A1 (en) * 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN110295152A (zh) * 2019-07-29 2019-10-01 北京泓恩生物科技有限公司 一种重组产朊假丝酵母尿酸酶的纯化方法
EP3906303A1 (en) 2019-12-06 2021-11-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
WO2022003565A1 (en) * 2020-07-01 2022-01-06 Medimmune, Llc Detergent and method for purifying a biotherapeutic
CN112062833A (zh) * 2020-10-09 2020-12-11 国药集团武汉血液制品有限公司 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法
CN115677848A (zh) * 2022-10-24 2023-02-03 通化安睿特生物制药股份有限公司 一种制备高纯度高稳定性蛋白质的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1991015581A1 (en) 1990-04-05 1991-10-17 Roberto Crea Walk-through mutagenesis
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
EP2380906A2 (en) 1997-06-12 2011-10-26 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DK1137812T3 (da) 1998-12-02 2007-05-21 Adnexus Therapeutics Inc DNA-proteinfusioner og anvendelser deraf
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2377468C (en) 1999-07-27 2010-04-20 Phylos, Inc. Peptide acceptor ligation methods
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
WO2003000856A2 (en) 2001-06-21 2003-01-03 Phylos, Inc. In vitro protein interaction detection systems
KR100524872B1 (ko) 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
WO2006023144A2 (en) 2004-07-06 2006-03-02 Bioren Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
MX2008008076A (es) * 2005-12-22 2008-11-28 Conjuchem Biotechnologies Inc Procesos para la produccion de conjugados preformados de albumina y un agente terapeutico.
CN102014888A (zh) 2007-07-03 2011-04-13 达努塔·克鲁谢夫斯卡 α-酮戊二酸的新医药用途
AU2008287426B2 (en) 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
JP2011501951A (ja) 2007-10-31 2011-01-20 メディミューン，エルエルシー タンパク質足場
HRP20161251T1 (hr) 2008-10-31 2016-11-18 Janssen Biotech, Inc. Platformski sastavi zasnovani na domeni fibronektina tipa iii, postupci i upotrebe
EP2396011B1 (en) 2009-02-12 2016-04-13 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
US9403898B2 (en) * 2009-05-07 2016-08-02 Novozymes Biopharma Dk A/S Method for purifying albumin
RU2607374C2 (ru) 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
US8697650B2 (en) 2010-02-16 2014-04-15 Medimmune, Llc HSA-related compositions and methods of use
AU2011240624B2 (en) 2010-04-13 2017-02-23 Medimmune, Llc TRAIL R2-specific multimeric scaffolds
CA2826683A1 (en) 2011-02-15 2012-08-23 Medimmune, Llc Hsa-related compositions and methods of use
DK2771022T3 (da) * 2011-10-11 2020-09-28 Viela Bio Inc Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
AU2013343503B2 (en) * 2012-11-08 2017-12-14 Albumedix Ltd. Albumin variants

Also Published As

Publication number Publication date
CN107428817B (zh) 2022-07-12
JP7320550B2 (ja) 2023-08-03
JP2018513124A (ja) 2018-05-24
AU2016228806A1 (en) 2017-08-31
AU2021200423B2 (en) 2023-04-06
WO2016145307A1 (en) 2016-09-15
IL253971B (en) 2021-10-31
EP3268389A4 (en) 2018-08-08
BR112017019401A2 (pt) 2018-05-02
US20180105575A1 (en) 2018-04-19
CA2977675A1 (en) 2016-09-15
JP2021105025A (ja) 2021-07-26
EP3268389B1 (en) 2020-09-30
US10683340B2 (en) 2020-06-16
ES2839211T3 (es) 2021-07-05
JP2023103368A (ja) 2023-07-26
AU2021200423A1 (en) 2021-02-25
US20200407423A1 (en) 2020-12-31
AU2023204271A1 (en) 2023-07-27
EP3268389A1 (en) 2018-01-17
KR20170124592A (ko) 2017-11-10
EP3842451A1 (en) 2021-06-30
US20230340074A1 (en) 2023-10-26
AU2016228806B2 (en) 2020-10-22
CN107428817A (zh) 2017-12-01
KR20240093725A (ko) 2024-06-24
IL253971A0 (en) 2017-10-31
US11548933B2 (en) 2023-01-10

Similar Documents

Publication Publication Date Title
JP6862348B2 (ja) アルブミン融合タンパク質を精製する方法
JP7560507B2 (ja) ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法
CN104768571A (zh) 多价异多聚体支架设计和构建体
JPWO2020116560A1 (ja) 抗体のＦｃ領域改変体
KR20250042176A (ko) 신생아 fc 수용체의 특정 에피토프에 결합하는 폴리펩타이드
JP2023508366A (ja) 二重特異性ｆｃｙｒｉｉｉ×ｃｄ３０抗体構築体の製造方法
KR20250148832A (ko) 알부민 융합 단백질의 정제방법
CN115702169A (zh) 包含促红细胞生成素多肽的融合蛋白
BR112017019401B1 (pt) Método de purificação de proteínas de fusão de albumina
BR122024023456A2 (pt) COMPOSIÇÃO COMPREENDENDO SUPORTES Tn3
RU2820588C2 (ru) Способы очистки гетеродимерных полиспецифических антител
HK1245286B (en) Method of purifying albumin-fusion proteins
HK40090436A (zh) Cd40l-特异性tn3-衍生的支架及其使用方法
RU2826189C2 (ru) Cd40l-специфичные каркасные структуры, происходящие из tn3, и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210331

R150 Certificate of patent or registration of utility model

Ref document number: 6862348

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250